BioPorto A/S’ strategy is to focus on developing and licensing antibodies and antibody-based products aimed at the basic research market segment. Through this market presence, BioPorto will monitor and act upon sales of specific antibodies and customer/distributor feedback. Selecting the promising monoclonal antibodies and document the clinical significance and market value will enable BioPorto to obtain further clinical acceptance and generate turnover in the routine diagnostic market.

BioPorto A/S will enter the routine diagnostic market through license and partnership alliances.